Aim: Resistin in serum is associated with high risk in patients with atherosclerosis. This clinical study aimed to investigate whether pitavastatin can regulate the serum level of resistin, together with levels of other inflammatory cytokines and adipocytokines. Methods: Forty two outpatients (mean age 65.2 12.6 yr, M/F: 21/21) with hypercholesterolemia were administered 2 mg of pitavastatin and serum levels of resistin, together with serum levels of adiponectin, leptin, TNF-alpha and hsCRP, were measured before, and 12 weeks after enrollment. Results: There was no significant gender-related difference in initial serum resistin levels. Pitavastatin significantly decreased LDL-cholesterol after 12 weeks. Initial levels of resistin showed a significant correlation with those of hsCRP (r 0.38, p 0.013), but not TNF-alpha or HOMA-R. Serum resistin, but not adiponectin and leptin, levels were significantly decreased, dropping from 17.1 9.9 ng/ dL to 15. 
resistin, and resistin affects human endothelial cell proliferation and migration; promotes capillary-like tube formation; upregulates the expression of vascular endothelial growth factor receptors (VEGFRs) and matrix metalloproteinases (MMPs); and activates the ERK1/2 and p38 pathways 5, 6) . From a clinical standpoint, a recent study reported a close association between serum resistin and carotid intima media thickness in hypertensive patients 7) . Furthermore, plasma resistin levels have been shown to increase in the presence of metabolic syndrome and cardiovascular diseases 8, 9) and to be an inflammatory marker of atherosclerosis in humans 10) . This body of evidence suggests that the secretion of resistin from macrophages may provide a therapeutic hint to the treatment of insulin resistance and atherosclerosis.
Pitavastatin, a synthetic 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor, has been available in Japan since July 2003. Pitavastatin taken daily is safe and efficacious in reducing LDLcholesterol levels as compared with atorvastatin 11) . An
Introduction
Insulin resistance is a major contributor to various metabolic disorders such as type diabetes and atherosclerosis. Adipocytokines are associated with the pathogenesis of insulin resistance 1) . Resistin, a 12.5-kDa cysteine-rich polypeptide, is a newly described adipocytokine which is mainly produced and secreted by macrophages in humans and adipose tissues in rodents. Resistin is considered to play an important role in the pathogenesis of insulin resistance and atherosclerosis 2, 3) . Recent studies have shown that resistin increases lipid accumulation in human macrophages through its upregulation of CD36 cell surface expression 4) . Macrophages infiltrating atherosclerotic aneurysms secrete in vitro study by Saiki et al. showed that pitavastatin enhanced the expression of lipoprotein lipase mouse 3T3-L1 preadipocytes more than did other statins (simvastatin and atorvastatin) 12) . Recent studies in vitro have demonstrated the beneficial pleiotropic effects of pitavastatin on the pathogenicity of macrophages in the progression of atherosclerosis. Han et al. showed that pitavastatin significantly increased the scavenger receptor class B type (SR-B ) mRNA and protein expression in a macrophage cell line in a concentration-and time-dependent manner through the inactivation of the transcription factor nuclear factor-kappaB (NF-kappaB) 13) . As SR-B , a receptor for high-density lipoprotein (HDL), plays an important role in the bidirectional exchange of cholesterol between cells and HDL particles, the enhancement of SR-B expression can reduce the development of atherosclerotic lesions. Furthermore, atherogenic remnant lipoproteins (RLPs) are known to induce foam cell formation from macrophages in vitro and in vivo. An in vitro study by Kawakami demonstrated that pitavastatin inhibited the RLP-induced formation of foam cells by macrophages, at least in part, through regulation of the involvement of the apoB48 receptor, a novel receptor for RLPs 14) . These preventative actions of pitavastatin suggested that the drug can also beneficially regulate resistin levels, which may lead to improvements in insulin resistance and atherosclerosis. However, to our knowledge, few reports have investigated the clinical effect of pitavastatin on serum resistin. This study aimed to evaluate the pleiotropic effects of pitavastatin on the serum resistin concentration.
Subjects
This study involved 42 outpatients of our hospital with hypercholesterolemia. Patient characteristics are shown in Table 1 . Before enrollment in the study, full informed consent was given by each patient. The study was conducted in compliance with the ethical rules specified by the Ethics Committee of our hospital in accordance with the Helsinki Declaration (as revised in Edinburgh in 2000). The study was approved by the ethics committee of Tohno-Kousei Hospital.
Methods
Two milligrams of pitavastatin was administered once a day to each subject, and blood laboratory examinations were performed before and following 12 weeks of administration. After each patient's fasting venous blood sample was obtained, routine laboratory tests including examinations of lipid profile and hepatic function, were conducted using an automated analyzer (TBA-120FR, Toshiba, Tokyo, Japan). Each patient's serum was immediately frozen at 70 and serum levels of adipocytokines were measured within 24 hours. Serum levels of resistin, adiponectin, leptin, TNF-alpha, and high sensitive C reactive protein (hsCRP) were measured using the Quantikine Human Resistin Immunoassay (R & D Systems, Minneapolis, MN, USA), adiponectin ELISA kit (Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan), leptin RIA kit (Linco Research Co. Ltd., USA), QuantiGlo Human TNFChemiluminescent Immunoassay (R & D Systems, Minneapolis, MN, USA), and N-latex CRP kit (Dade Behring USA), respectively. Height (measured to the nearest 0.1 cm), weight (measured to the nearest 0.1 kg), and waist circumference (measured to the nearest 0.1 cm) of the patients were measured by trained staff. The waist circumference was measured horizontally at the level of the umbilicus.
Statistical Analyses
Data is reported as the mean SD. A paired Student's t test was used to compare each blood level before pitavastatin administration and after 12 weeks. A single regression analysis was used to assess the correlation between serum resistin and other indexes including hsCRP. Statistical analyses were carried out by JMP version 5.0.1a (SAS Institute Inc., Cary, NC, USA) with the significance level set at 5%.
Results

Base Laboratory Values
Laboratory data including serum resistin levels at enrollment are listed in the left column of Table 2 . Initial levels of resistin were significantly correlated with those of hsCRP (r 0.38, p 0.013) ( Fig. 1) and TG (r 0.59, p 0.001), but not with the other indexes including TNF-alpha and HOMA-R (data not shown). Furthermore, there was no significant difference in initial resistin levels between males and females (data not shown). Table 2 also shows changes in select blood laboratory indexes over 12 weeks. Serum levels of total cholesterol, LDL-cholesterol, and cholinesterase significantly changed over 12 weeks. In addition, serum levels of resistin also significantly improved from 17.1 9.9 ng/mL to 15.2 10.0 ng/mL (p 0.001) over 12 weeks, while adiponectin, leptin, hsCRP and TNFalpha levels did not.
Changes in Various Blood Laboratory Indexes Over 12 Weeks
When the patient group was stratified on the basis of hsCRP 0.1 mg/dL and 0.1 mg/dL, the group whose initial hsCRP value was greater than or equal to 0.1 mg/dL demonstrated a significant increase in initial levels of resistin, and both levels of resistin and hsCRP were significantly decreased after 12 weeks treatment with pitavastatin (p 0.011 and p 0.022, respectively) (Fig. 2) . On the other hand, serum levels of resistin, but not hsCRP, significantly decreased after the treatment (p 0.010) in the group whose initial hsCRP value was less than 0.1. When we focused on the patients whose serum resistin levels decreased following 12 weeks of treatment, the changes in HbA1c, hepatic function indexes (AST, ALT and gamma-GTP), and creatine kinase were significantly correlated with those in resistin ( Table 3) .
Discussion
This study demonstrated that pitavastatin significantly reduced serum resistin levels following 12 weeks of therapy, which did not significantly correlate with a decrease in total cholesterol and LDL-cholesterol levels. Therefore, this reduction can be regarded as an important pleiotropic effect of pitavastatin to prevent the progression of atherosclerosis. As mentioned above, resistin plays an important role in the pathogenesis of insulin resistance and atherosclerosis 2, 3) . However, no previous studies have directly investigated the mechanism by which pitavastatin reduces resistin secretion, and the precise mechanism is unclear. Furthermore, in spite of the significant reduction in the level of resistin in this study, the HOMA-R level did not significantly improve during the 12-week period, suggesting that a longer period may be required to evaluate the improvement in insulin resistance after the administration of pitavastatin.
The reduction in the level of resistin caused by pitavastatin suggested the clinical possibility of preventing the progression of atherosclerosis. As described above, macrophages which accumulate in atherosclerotic plaques predominantly secrete resistin 4) . The resistin secreted by macrophages subsequently stimulates production of the pro-inflammatory cytokines TNFalpha and IL-12 in macrophages by an NF-kappaBdependent pathway 15) , the accumulation of lipids in macrophages 16) , and the proliferation and migration of human endothelial cells 5, 6) . In addition to many recent studies concerning the inhibitory effects of pitavastatin on aortic smooth muscle cells and vascular endothelial cells [17] [18] [19] [20] , there are reports of the suppressive effects of pitavastatin on macrophage accumulation and functions. Pitavastatin enhanced the expression of SR-B in macrophages which can reduce the development of atherosclerotic lesions through the inactivation of the transcription factor NF-kappaB 13) and inhibition of the RLP-induced formation of foam cells by macrophages partly through the regulation of the apoB48 receptor 14) . A recent experimental study by Suzuki et al. showed that 16 weeks of treatment with pitavastatin reduced the macrophage-positive area in the rabbit aortic plaque by 39.4% and increased the areas occupied by collagen and alpha-smooth muscle actin (alpha-SMA) by 66.4 and 91.7%, respectively 21) . Furthermore, pitavastatin reduced the areas containing monocyte chemoattractant protein (MCP)-1, MMP-3, and MMP-9 by 39.1, 40.6, and 52.3% in rabbit aorta, respectively. A recent in vitro study by Ichida et al. reported that serum resistin concentrations tended to decrease after 6 months of atorvastatin treatment 22) . Shetty et al. showed a 20%, but not statistically significant, reduction of plasma resistin after atorvastatin treatment in a 12-week-long randomized, double-blind and placebo-controlled study of patients with type 1 or type 2 diabetes and patients in a prediabetic state 23) . They also found a positive correlation of resistin with C-reactive protein (CRP) in a cross-sectional study. Another recent 8-week-long randomized, open and placebo-controlled study by von Eynatten et al. reported that atorvastatin significantly reduced plasma levels of resistin and leptin in patients with type 2 diabetes and also that resistin levels were correlated positively with plasma CRP (r 0.35, p 0.005) and negatively with HDL cholesterol (r 0.26, p 0.02) 24) . These studies suggest that statins including pitavastatin have a reductive effect on preventing the release of resistin from macrophages as well as anti-inflammatory and anti-atherosclerotic pleiotropic effects. Furthermore, pitavastatin can significantly reduce serum resistin levels in almost the same short period of time as atorvastatin.
As shown in Fig. 1 , initial levels of resistin in serum were significantly correlated with those of hsCRP (r 0.38, p 0.013) at enrollment in this study. The result was almost the same as the one reported by McTernan et al. (r 0.39, p 0.04) 25) . However, the changes in resistin over 12 weeks were not significantly correlated with those in hsCRP ( Table 2 ). In the group of patients whose initial hsCRP values were greater than or equal to 0.1 mg/dL at enrollment, levels of both resistin and hsCRP were significantly decreased after 12 weeks of treatment with pitavastatin. In contrast, the patients whose initial hsCRP values were initially less than 0.1 mg/dL only had decreased resistin levels (Fig. 2) . This suggested that pitavastatin directly and independently reduced resistin levels through a different mechanism from that acting on hsCRP. In other words, pitavastatin does not unnecessarily suppress inflammation further when the levels of hsCRP is not elevated excessively.
This study also demonstrated that, when focusing on patients whose serum resistin levels decreased following 12 weeks of treatment, the change in resistin levels was significantly correlated with that in hepatic function indexes (AST, ALT and gamma-GTP) after 12 weeks (Table 3) . A recent study by Yagmur et al. demonstrated that serum resistin levels were significantly elevated in patients with liver cirrhosis compared with healthy controls (p 0.001) 26) . Levels of resistin also increased with the stage of liver cirrhosis as defined by the Child-Pugh classification or the model for end-stage liver disease (MELD) score, and also correlated inversely with markers of hepatic biosynthetic capacity and positively with markers of inflammation such as TNF-alpha and CRP 26) . Another study showed increased serum concentrations of resistin in cases of nonalcoholic fatty liver disease, which was related to disease severity 27) . Resistin gene expression is weak in normal human liver, but is up-regulated in patients with hepatic fibrosis due to chronic liver damage. An in vitro study demonstrated a pivotal role for resistin as an intrahepatic cytokine exerting proinflammatory effects in activated human hepatic stellate cells (HSCs), key modulators of hepatic fibrogenesis 28) . Exposure of cultured HSCs to recombinant resistin resulted in increased expression of MCP-1 and interleukin-8 through activation of NF-kappaB 28) . These findings are not inconsistent with the results of this study.
In conclusion, the pleiotropic effect of pitavastatin on resistin encouraged us to further investigate its effects on macrophages to prevent the progression of atherosclerosis.
